Table 1.
Ocular characteristics (patients and eyes analyses populations) at the initiation of ranibizumab 0.5 mg treatment
| Characteristica | Patient analysis population N = 72 | Eyes analysis population N = 98 | |
|---|---|---|---|
| First treated eye N = 72 | Contralateral eye N = 72 | ||
| Angioid streaks, n (%) | 66 (91.7) | 56 (77.8) | 73 (74.5) |
| CNV leakage, n (%) | 51 (70.8) | 21 (29.2) | 50 (51.0) |
| Retinal hemorrhages, n (%) | 34 (47.2) | 10 (13.9) | 33 (33.7) |
| CNV, n% | 64 (88.9) | 30 (41.7) | 76 (77.6) |
| Location | 64 | 30 | 76 |
| Subfoveal | 24 (37.5) | 12 (40.0) | 25 (32.9) |
| Juxtafoveal | 23 (35.9) | 8 (26.7) | 28 (36.8) |
| Extrafoveal | 19 (29.7) | 9 (30.0) | 19 (25.0) |
| Unspecified | 3 (4.7) | 5 (16.7) | 5 (6.6) |
| VA (ETDRS letters), mean (±SD) | 65.4 (±19.4) (n = 54) | 57.5 (±27.3) (n = 45) | – |
| CRT (μm), mean (±SD) | 298.7 (±134.7) | 256.7 (±79.8) | 291.1 (±133.2) |
aPatients with absent ocular characteristic and those with missing data are excluded
CNV, choroidal neovascularization; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; SD, standard deviation; VA, visual acuity